3 Stocks Pushing The Drugs Industry Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (-0.0%) at 12,538 as of Friday, Nov. 16, 2012, 2:44 PM ET. The NYSE advances/declines ratio sits at 1,873 issues advancing vs. 1,148 declining with 77 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is up 0.0%. Top gainers within the industry include Regeneron Pharmaceuticals ( REGN), up 11.9%, Gilead ( GILD), up 2.5% and Bristol-Myers Squibb Company ( BMY), up 2.6%. A company within the industry that fell today was Eli Lilly and Company ( LLY), up 0.2%.

TheStreet Ratings group would like to highlight 3 stocks pushing the industry higher today:

3. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Valeant Pharmaceuticals International is up $1.63 (3.1%) to $54.95 on heavy volume Thus far, 1.4 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $53.05-$55.32 after having opened the day at $53.06 as compared to the previous trading day's close of $53.32.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $16.3 billion and is part of the health care sector. The company has a P/E ratio of 669.5, above the S&P 500 P/E ratio of 17.7. Shares are up 14.7% year to date as of the close of trading on Thursday. Currently there are 11 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we find that net income has been generally deteriorating over time. Get the full Valeant Pharmaceuticals International Ratings Report now.

If you liked this article you might like

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year

Beleaguered Hedge Fund Titan Bill Ackman Is Having Another Rough Year